Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer... Show more
A.I.dvisor indicates that over the last year, VSTM has been loosely correlated with ZYME. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if VSTM jumps, then ZYME could also see price increases.
| Ticker / NAME | Correlation To VSTM | 1D Price Change % | ||
|---|---|---|---|---|
| VSTM | 100% | -0.40% | ||
| ZYME - VSTM | 44% Loosely correlated | +0.53% | ||
| SRPT - VSTM | 44% Loosely correlated | +1.41% | ||
| ABEO - VSTM | 41% Loosely correlated | -2.05% | ||
| LXEO - VSTM | 41% Loosely correlated | -3.57% | ||
| DYN - VSTM | 39% Loosely correlated | +0.64% | ||
More | ||||
a company that discovers and develops drugs
Industry Biotechnology
VSTM saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 73 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
The Moving Average Convergence Divergence (MACD) for VSTM just turned positive on October 15, 2026. Looking at past instances where VSTM's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.
VSTM moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +23.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where VSTM advanced for three days, in 205 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 155 of 188 cases where VSTM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
VSTM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.118) is normal, around the industry mean (3.037). P/E Ratio (-4.098) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.